ESR1 and breast cancer: The response to treatment and prognosis of BC relies on molecular characteristics that have been well established, and the molecular type based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) status shows excellent performance for guiding clinicians to select the optimal treatment for BC patients in the past few decades (4, 5).